Bargain hunters should love these great stocks. By most metrics, the stock market is priced at a premium these days. But that doesn't mean bargains can't still be found. Three Motley Fool contributors think they've identified dirt-cheap healthcare stocks to buy right now. Here's why they picked CRISPR Therapeutics (CRSP -2.65%), Gilead Sciences (GILD 0.05%), and Pfizer (PFE -0.81%). You can still get in on the ground floor Prosper Junior Bakiny (CRISPR Therapeutics): Valuing relatively small biotech compani ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $49.49, moving -0.2% from the previous trading session. This change lagged the S&P 500's 1.7% gain on the day. Elsewhere, the Dow gained 1.26%, while the tech-heavy Nasdaq added 2.51%. The the stock of company has fallen by 0.8% in the past month, lagging the Medical sector's gain of 1.53% and the S&P 500's gain of 1.27%. Analysts and investors alike will be keeping a close eye on the performance of CRISPR Therapeutics AG in its upcoming ea ...

There's a lot of growth on the way, and soon. CRISPR Therapeutics' (CRSP -0.56%) stock may be down by 21% this year so far, but that doesn't mean you should write it off as a potential investment. The innovative developer of gene therapies is making headway. And its pipeline implies a cornucopia of opportunities for the stock to rise over the coming years, especially if its cardiovascular medicine and oncology programs pan out. Still, investing in biotech companies isn't for the faint of heart, and even a s ...

I am a former Senior Manager at a Big Four accounting firm and have been a CPA for over 20 years. After leaving public accounting in 2010, I have been the CFO of two privately held companies with sales between $50m and $100m in both the aerospace and defense and beauty industries. At my core, I like to think of myself as a value investor, though I will step into other disciplines if I think it makes sense. I have been investing since 1999, so I have seen a few different market cycles and have tried my hand ...

It's an excellent opportunity to buy shares of what could become a biotech giant on the dip. In the past three years, CRISPR Therapeutics (CRSP -0.33%) has made tremendous progress. It was still a clinical-stage biotech in 2021, but it now has a gene-editing therapy that is approved in multiple countries. However, this regulatory milestone hasn't been accompanied by a strong stock market performance. CRISPR Therapeutics has significantly lagged the market since 2021. What is going on with this gene-editing ...

An investment in these players today could score a big win down the road. Why do investors love biotech stocks? Because these players often work on game-changing technology that could lead to tomorrow's game-changing treatment -- and potentially blockbuster revenue. As an investor, you often have to be patient, as it takes years for a company to bring a candidate through development and reach the billion-dollar revenue stage. And you have to be comfortable with a bit of risk too, because candidate failure a ...

Is the potential upside for CRISPR Therapeutics too massive to ignore? There was a lot of hype and excitement around gene-editing company CRISPR Therapeutics (CRSP -1.08%) last year after it obtained approval for its first product, Casgevy. But that excitement has largely waned, and investors appear to have moved on from the stock. Year to date, shares of CRISPR are down 24%, and it is nowhere near its 52-week high of more than $91. Is there something wrong with the business, or could the decline in price m ...

A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP) . Shares have lost about 7.7% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts. Q2 Loss Wider-Than-Expected, S ...

These companies are nearly in the sweet spot of risk versus reward in biotech. Many investors rightfully identify biotech stocks as being riskier than average, and those stocks certainly have a habit of earning their reputation. Still, there are a few up-and-coming biotechs that have revenue and a clear path to generating even more in the near term, which makes them notably steadier than their earlier-stage peers that don't yet have the certainty of selling anything at all. With that in mind, let's examine ...

The companies are chasing major innovations. Exciting trends are sweeping through the biotech industry. One of them is the race to develop breakthrough weight loss medicines, an area that is projected to grow by leaps and bounds through the end of the decade. Gene editing, a set of techniques that are allowing researchers to unlock therapies for diseases that have been untouchable, is another one. Companies, particularly relatively small ones that make breakthroughs in these fields, could deliver marketcrus ...